Guildford’s Ergomed PLC report £27m revenue increase in 2022

Ergomed PLC, a Guildford-based company that provides specialised services to the pharmaceutical industry, today released its Full Year Results for 2022 with reports of growth in both revenue and EBITDA.

The company reported that revenues were up 23 per cent, rising from £118.6 million to £145.3million. Ergomed’s EBITDA was up 11.5 per cent, rising from £25.4million to £28.4million.

This follows Ergomed’s £24.2 million acquisition of international consultancy ADAMAS, completed in February 2022, which was highlighted in the report as pivotal to the company’s expansion. The appointments of new Chief Transformation & Technology officer and new CFO Jonathan Curtain were also mentioned as very important to the company’s success last year.

Executive Chairman of Ergomed Dr Miroslav Reljanović said: ‘’During 2022, Ergomed delivered another year of strong revenue and EBITDA growth. The successful acquisition of ADAMAS further endorsed our acquisition strategy and capabilities, and we remain focused on delivering further organic and inorganic growth aligned to our strategic priorities.

‘’As we look ahead to 2023, demand for our services is high, and our focus continues to be on operational excellence and delivering a market leading service as a global provider of specialist pharmaceutical services addressing unmet medical needs and patient safety."

Read more – Oxford Nanopore Technologies posts full-year revenues of £200m